Hypertensive pulmonary vascular disease is characterized by abnorprostanoids (7), which dilate reactive blood vessels and sup- 
kinase growth factor membrane receptors to the intracellular oxide synthase mitogen-activated protein/extracellular signal-regulated kiHypertensive pulmonary vascular disease presents with insidnase inflammatory/proliferative signaling pathways (18, 19) . ious dyspnea on exertion and is characterized pathophysioIn pulmonary vein endothelial cells, simvastatin blocks actilogically by pulmonary arterial hypertension and progressive vation of the calcium-dependent focal-adhesion tyrosine kiright ventricular failure. The pathological changes of hypernase, Pyk2, necessary for angiotensin II receptor-mediated tensive pulmonary vascular disease involve abnormal proinflammatory signaling (20) . Simvastatin inhibited human liferation of vascular endothelial and smooth muscle cells, aortic vascular smooth muscle cell proliferation through inresulting in occlusion of the lumen of small pulmonary arduction of the cell cycle inhibitor, p27 Kip1 (18) . Statins also teries (1) (2) (3) . Mutations in the bone morphogenetic protein improve endothelium-dependent relaxation through mechareceptor Type II (BMPR2) have been demonstrated in panisms that involve stabilization of endothelial nitric oxide tients with familial and sporadic primary pulmonary hypersynthase (eNOS) mRNA during hypoxia (21), and enhancetension (PPH) (4, 5) . Defective BMPR2 signaling may conment of Akt/protein kinase B phosphorylation of eNOS, leadtribute to the intimal proliferation and vascular obliteration ing to increased production of nitric oxide (22) . Statins supof small pulmonary arterioles in PPH (6) . The best currently pressed neointimal formation and vascular narrowing after established treatments for PPH involve administration of balloon injury of carotid arteries in normocholesterolemic rabbits (23).
On the basis of the benefits demonstrated by statins in
(Received in original form March 29, 2002 ; accepted in final form August 6, 2002) decreasing neointimal vascular occlusion and improving blood flow in the systemic arterial circulation (17, 24-27), we groups survived for the duration of the study and underwent
METHODS
hemodynamic measurements followed by sacrifice on postopera-
Study Sample
tive Day 35. The normal group consisted of six normal, healthy
Thirty pathogen-free, 13-week-old, male Sprague-Dawley rats (body rats that were included as a reference control group for changes weight, 350-400 g) were studied.
in body weight, hemodynamic parameters, organ weights, and histopathology.
Left Pneumonectomy
On Day 0, rats were intubated, anesthetized with halothane (0.5%), and Body Weights then underwent left pneumonectomy via left thoracotomy, as previously described (10, 11) .
During the 35-day study period, rats in the normal group increased in body weight by 18%. In contrast, Group PMV rats,
Monocrotaline Administration
which developed severe hypertensive pulmonary vascular disOn Day 7, rats were injected subcutaneously in the right hind limb ease after pneumonectomy, monocrotaline injection, and vehicle with monocrotaline (60 mg/kg; Sigma, St. Louis, MO). treatment, decreased in body weight by 15%. Rats treated with simvastatin after pneumonectomy and monocrotaline injection
Treatment Groups
preserved their body weights (data not shown).
Rats were randomized to receive simvastatin or vehicle by daily gavage. Five groups were studied: Group PMS (whole treatment group) Hemodynamic Parameters received simvastatin (2 mg/kg per day) from Day 5 to Day 35 (n ϭ 6), Group PMS [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] (early treatment group) received simvastatin (2 mg/kg Hemodynamic measurements of rats in the normal group demper day) from Day 5 to Day 14 (n ϭ 6), and Group PMS ures 1A and 1B). Rats in Group PMS (whole treatment) had measured as previously described (10, 11) . After exsanguination, the right lung, right ventricle, and left ventricle plus septum were collected the lowest (Ppa) (27 Ϯ 3 mm Hg) and Prv,s (37 Ϯ 4 mm Hg) for histology (10, 11) . The severity of neointimal formation was scored values. Rats in Group PMS to detect whether early or late treatment with simvastatin produces any significant effects compared with vehicle and whether there is any Histopathology interaction between early and late simvastatin treatments. A value of p Ͻ 0.05 was considered statistically significant.
Representative small pulmonary arteries from normal rats and pneumonectomized, monocrotaline-injected rats treated with
RESULTS
vehicle or simvastatin are shown, stained for elastin to reveal the inner elastic lamina (Figures 3A-3E) . A quantitative analysis Twenty-four rats received monocrotaline (60 mg/kg, subcutaneous), 7 days after pneumonectomy. All rats in the four treatment of lumenal obstruction in 25 consecutive small pulmonary arter- rats (each group, n ϭ 6). Figure 1 . Simvastatin prevents the development of pulmonary arterial hypertension in pneumonectomized, monocrotaline-treated rats. Shown are measurements of (A ) mean pulmonary artery pressure (mean (Ppa), or mPAP) and (B ) right ventricular systolic pressure (Prv,s, or Rats treated with simvastatin showed significant decreases in RVSP) in normal (control) group, Group PMV, Group PMS , Group VOS compared with vehicle-treated rats. Rats in Group PMS PMS [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , and Group PMS rats (each group, n ϭ 6).
showed a VOS of 0.59 Ϯ 0.46, rats in Group PMS [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] showed a VOS of 0.78 Ϯ 0.40, and rats in Group PMS showed a VOS of 0.93 Ϯ 0.38. Two-way ANOVA and multiple comparison ies from each rat in the normal group and Groups PMV, PMS , revealed that significant effects of simvastatin treatment on VOS PMS [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , and PMS was performed. The distribution of the occurred in both the early simvastatin treatment group (Group vascular lesions, and an average vascular occlusion score (VOS)
PMS [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , p Ͻ 0.001) and in the late simvastatin treatment group between 0 and 2, are presented ( Figure 3F ). Rats in Group PMV (Group PMS , p Ͻ 0.001). The improvements in VOS achieved developed severe pulmonary vascular remodeling with a VOS in all groups treated with simvastatin substantially exceeded the of 1.98 Ϯ 0.02 ( Figure 3B versus Figure 3A ) (10, 11) .
best improvements achieved with triptolide (VOS ϭ 1.27 Ϯ 0.61) Figure 3 . Simvastatin attenuates pulmonary artery neointimal formation. The vascular occlusion score is the average score for 25 consecutive intra-acinar pulmonary arteries. Vessels were assessed for neointimal proliferative lesions and score: Grade 0 for no evidence of neointimal formation, Grade 1 for less than 50% lumenal occlusion, and Grade 2 for greater than 50% lumenal occlusion. (A ) Normal rat intra-acinar artery (Grade 0) (elastin-van Gieson stain; original magnification, ϫ600); (B ) Grade 2 neointimal lesion (Ͼ 50% narrowing) in pneumonectomized rats, 4 weeks after receiving monocrotaline (60 mg/kg, subcutaneous (late treatment group) rats (each group, n ϭ 6). Figure 4D to stain only cells lining the vascular lumen. We used electron microscopy to further characterize the neointimal lesions ( Figures 4E and 4F ) and show the presence of alternating plaques and caveolae at the surface. No fibronectin fibrils or fibronexus junctions, which are features of myofibroblastic differentiation, were seen. Taken together, the presence of ␣-smooth muscle actin and these ultrastructural findings identifies these cells in the neointima to be smooth muscle cells (32). in diseased rats (Group PMV) than in normal rats ( Figure 5B ).
CD31 monoclonal antibody is shown in

ϫ80,000.
Simvastatin treatment increased expression of eNOS in pneumonectomized, monocrotaline-injected rats, although this trend did not achieve statistical significance. The lung expression of eNOS protein was assessed qualita-VOS ϭ 1.57 Ϯ 0.1) (11) .
tively by Western immunoblotting ( Figure 5C ). An eNOS antiseThe cellular phenotype of the pulmonary microvascular neorum-immunoreactive band is detected at 130 kDa ( Figure 5C ). intimal occlusive lesions was characterized. Hematoxylin-and Compared with normal rats, diseased rats in Group PMV showed eosin-stained lung sections from Group PMV rats demonstrate decreased expression of eNOS protein, and simvastatin treatextensive occlusion of small pulmonary arterioles, with preservament restored eNOS expression toward the level in normal rats tion of alveolar structures ( Figures 4A and 4B ). These consisted ( Figure 5C ). of concentric laminar proliferations of spindled cells. Plexiform lesions in muscular pulmonary arteries were not observed. Im-DISCUSSION munohistochemical staining reveals the presence of ␣-smooth Pulmonary arterial hypertension involves histopathological muscle actin staining in many of the cells forming the neointima ( Figure 4C) . A marker of endothelial cells is CD31; an antichanges of medial hypertrophy, intimal proliferation, and occlu-sion of microvascular pulmonary arteries and, in severe cases, induction of eNOS and improvements in endothelium-depenplexiform arteriopathy (2) . The nature and origin of the cells dent vasodilation (27). We infer that simvastatin improved pulpresent in the obstructing intimal lesions represent important monary vascular blood flow from the decreases in mean pulmoquestions for further understanding of the pathogenesis of hypernary arterial pressures, decreases in right ventricular hypertrophy, tensive pulmonary vascular disease. In a comprehensive analysis and decreases in vascular occlusion scores on histology. Continuof 53 lungs from patients with moderate to severe pulmonary ous treatment with simvastatin resulted in a Ppa of 27 mm Hg arterial hypertension (as a consequence of primary pulmonary compared with 53 and 17 mm Hg in vehicle-treated and normal hypertension, Eisenmenger's syndrome, and chronic thromborats, respectively. This decrease achieved with simvastatin apembolic disease), Yi and coworkers (2) demonstrated that most peared greater than that with triptolide (21 versus 42 mm Hg) cells within intimal lesions stained positive for ␣-smooth muscle (10) or with a rapamycin derivative, SDZ-RAD (25 versus 41 actin, and negative for endothelial markers, which the authors mm Hg) (11) . Simvastatin treatment appeared to produce greater proposed as support for a myofibroblastic phenotype. Only a protection against the development of right ventricular hypertrosingle layer of cells that lined the vascular lumen stained posiphy (RV/LVϩS, 0.34 versus 0.78) than did triptolide (RV/LVϩS, tively for endothelial markers, CD31 and Factor VIII (2). The 0.39 versus 0.69) or SDZ-RAD (RV/LVϩS, 0.42 versus 0.55). results of Yi and coworkers (2) differ from the earlier description Simvastatin treatment appeared to produce a greater decrease by Tuder and coworkers (33) , who used Factor VIII immunorein neointimal formation (VOS ϭ 0.59) compared with triptolideactivity to propose an endothelial origin of the cells present in treated (VOS ϭ 1.27), RAD-treated (VOS ϭ 1.57), and control plexiform lesions of patients with PPH. These differing historats with hypertensive pulmonary vascular disease (VOS ϭ 1.98). pathological results might be reconciled in light of demonstraSimvastatin attenuated hypertensive pulmonary vascular disease tions that transforming growth factor-␤ can induce a small persignificantly in both the early and late treatment groups. The centage of endothelial cells to transdifferentiate into smooth efficacy of simvastatin in the late treatment group suggests its muscle-like cells (34) (35) (36) . The transdifferentiating endothelial ability to rescue animals from established hypertensive pulmocells simultaneously stained positive with antibodies against Facnary vascular disease. tor VIII-related antigen and ␣-smooth muscle actin (34, 36) .
In other systems, simvastatin has been demonstrated to inOur model of hypertensive pulmonary vascular disease in hibit vascular smooth muscle cell proliferation in vitro (18) and pneumonectomized, monocrotaline-injected rats reproduces the in vivo (19) and to suppress neointimal proliferation (19, 23) . neointimal proliferation and vascular occlusion by smooth musIn this model of hypertensive pulmonary vascular disease, we cle cells that occurs in human pulmonary arterial hypertension.
demonstrate that simvastatin attenuates neointimal proliferation When rats are injected with the Crotalaria toxin, monocrotaline, and decreases pulmonary arterial hypertension through mechathere is hepatic metabolism of the monocrotaline into monocronisms that likely involve inhibition of pulmonary vascular smooth taline pyrrole, which then produces first-pass injury to the pulmomuscle cell proliferation in vivo. nary artery endothelial cells (31, 37) . Endothelial injury by monoHuman patients with pulmonary hypertension show reduced crotaline pyrrole leads to diminished barrier function, allowing expression of eNOS (42). Our demonstration of reduced expresextravascular leakage of proteases such as serum elastase and sion of eNOS in diseased rats further supports the similarities thrombin that act on extracellular matrix components and vascubetween our experimental model and human hypertensive pullar cells to trigger an inflammatory response (15, 37, 38) . Endomonary vascular disease. Simvastatin induces expression of thelial injury followed by an inflammatory response and eventual eNOS in vitro (21). We show that simvastatin augmented lung neointimal vascular occlusion by smooth muscle cells represents expression of eNOS mRNA and protein in diseased rats. In a valid and important model system for understanding the develother systems, simvastatin augmentation of eNOS expression opment and progression of small-vessel obliterative, hypertenand stimulation of eNOS phosphorylation by protein kinase Akt sive pulmonary vascular disease in humans.
were associated with enhanced production of the vasodilator We demonstrate that simvastatin is effective at attenuating nitric oxide (22) . vascular remodeling with neointimal formation, pulmonary arterial
The efficacy of simvastatin in attenuating neointimal vascular hypertension, and right ventricular hypertrophy in pneumoocclusion, pulmonary hypertension, and right ventricular hypernectomized, monocrotaline-injected rats. We previously charactrophy in this model suggests again the utility of antiproliferative terized the effects of two immunosuppressants with antiproliferatreatment strategies for hypertensive pulmonary vascular disease tive effects, triptolide (10) and rapamycin (11), using this (10, 11) . We propose that simvastatin attenuation of hypertenexperimental model. What mechanisms are involved in the effisive pulmonary vascular disease involves a combination of (1 ) cacy of simvastatin in attenuating hypertensive pulmonary vascuantiproliferative effects on pulmonary vascular smooth muscle lar disease? cells, (2 ) antiinflammatory effects that include decreases in endoAlthough less immunosuppressive than either triptolide or thelial MHC Class II expression, and (3 ) induction of endothelial rapamycin, statins do modulate the immune response by represscell eNOS expression and restoration of endothelium-dependent ing MHC Class II-mediated T cell activation (39) . Immunosuppulmonary vasodilation. pressive and antiinflammatory properties of statins may contribAn important question raised by this study is whether simvasute to the improved outcome of cardiac transplant patients under tatin treatment can reverse established neointimal vascular octreatment with pravastatin (40) and to the improved survival of clusion and pulmonary hypertension. We have developed a new patients with atherosclerosis, recognized to be a chronic inflammodel of chronic pulmonary arterial hypertension in rats for matory disease (16, 17, 41 ). Our rat model of hypertensive pulevaluation of rescue therapies such as simvastatin (T. Nishimura, monary vascular disease involves an early inflammatory response unpublished data). We suggest that simvastatin should be evaluafter monocrotaline-induced injury of pulmonary endothelial ated both for prevention of pulmonary hypertension in geneticells (37), followed subsequently by a vascular proliferative recally susceptible patients (43) as well as for treatment of patients sponse that produces pulmonary hypertension. The efficacy of with established pulmonary hypertension. simvastatin in the whole and early treatment groups of our disease model may involve antiinflammatory effects.
